7 research outputs found

    Involvement of LPA Receptor 3 in LPA-induced BGC- 803 Cell Migration

    No full text
    Lysophosphatidic acid Ë„ LPA Ë… is a bioactive phospholipid mediator, which elicits a variety of biological functions mainly through G-protein coupled receptors. Although LPA is shown to stimulate proliferation and motility via LPA receptors, LPAR1 and LPAR3 in several cancer cell lines, but the role of LPA receptors in gastric cancer cells is still being unknown. However, several researches reported that LPAR2 play an important role in the carcinogenesis of gastric cancer, but there is no report to show the LPAR3 involvement in the carcinogenesis. For this reason, we examined LPA receptors (LPAR1, LPAR2 and LPAR3) in BGC-803 cells along with real time PCR method. Real-time PCR analyses were used to evaluate the expression of LPA receptors in BGC-803 cells. Among these receptors, LPAR3 was shown to be highly expressed in BGC-803 cells, a human gastric cancer cell line. Transient transfection with LPAR3 siRNA was observed to reduce LPAR3 mRNA in BGC-803 cells and eliminate the LPA-induced cell migration. The results suggest that the LPAR3 regulates LPA-induced BGC-803 cell migration

    Controllable Synthesis of a Smart Multifunctional Nanoscale Metal–Organic Framework for Magnetic Resonance/Optical Imaging and Targeted Drug Delivery

    No full text
    As a result of their extraordinarily large surfaces and well-defined pores, the design of a multifunctional metal–organic framework (MOF) is crucial for drug delivery but has rarely been reported. In this paper, a novel drug delivery system (DDS) based on nanoscale MOF was developed for use in cancer diagnosis and therapy. This MOF-based tumor targeting DDS was fabricated by a simple postsynthetic surface modification process. First, magnetic mesoporous nanomaterial Fe-MIL-53-NH<sub>2</sub> was used for encapsulating the drug and served as a magnetic resonance contrast agent. Moreover, the Fe-MIL-53-NH<sub>2</sub> nanomaterial exhibited a high loading capacity for the model anticancer drug 5-fluorouracil (5-FU). Subsequently, the fluorescence imaging agent 5-carboxyfluorescein (5-FAM) and the targeting reagent folic acid (FA) were conjugated to the 5-FU-loaded Fe-MIL-53-NH<sub>2</sub>, resulting in the advanced DDS Fe-MIL-53-NH<sub>2</sub>-FA-5-FAM/5-FU. Owing to the multifunctional surface modification, the obtained DDS Fe-MIL-53-NH<sub>2</sub>-FA-5-FAM/5-FU shows good biocompatibility, tumor enhanced cellular uptake, strong cancer cell growth inhibitory effect, excellent fluorescence imaging, and outstanding magnetic resonance imaging capability. Taken together, this study integrates diagnostic and treatment aspects into a single platform by a simple and efficient strategy, aiming for facilitating new possibilities for MOF use for multifunctional drug delivery
    corecore